Key statistics dashboard for Lexaria Bioscience Corp. (LEXX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream.
Stock Data
| Price | $3.10 |
| Market Cap | $5M |
| Beta | 0.48 |
| Exchange | NASDAQ |
| Country | CA |
Valuation Multiples
| P/E Ratio | -0.58 |
| Price / Book | 1.08 |
| P/S | 26.36 |
| P/FCF | -0.68 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -3987.65% |
| EBITDA Margin | -3958.08% |
| Operating Margin | -3973.16% |
| Net Margin | -3985.58% |
Financial Health
| Current Ratio | 10.60 |
| Quick Ratio | 10.60 |
| Cash Ratio | 9.06 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.81% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -23.89 |
Per-Share Data
| Revenue per share | 0.12 |
| Book Value per share | 2.63 |
| Cash per share | 2.19 |
| FCF per share | -4.55 |
| Tangible Book Value per share | 2.42 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |